FOR IMMEDIATE RELEASE
Brainreader Appoints Steve Green as Head of U.S. Sales
Brainreader, a leader in advanced neuroimaging and brain volumetrics, today announced the appointment of Steve Green as Head of U.S. Sales. In this role, Mr. Green will lead the company’s U.S. commercial strategy, oversee sales execution, and drive market expansion for Brainreader’s AI-driven brain volumetric solutions across health systems, academic medical centers, and strategic partners.
Mr. Green brings more than 25 years of senior commercial sales and business development experience across the medical imaging, medical device, and biotech/biopharma markets. He has a proven track record of building and scaling high-performing commercial organizations, expanding market access, and delivering sustained revenue growth through strategic partnerships with National and Regional Healthcare Systems, the U.S. Department of Veterans Affairs, OEMs, and clinical stakeholders.
Throughout his career, Mr. Green has been recognized for aligning clinical value, operational execution, and corporate strategy to drive adoption of advanced imaging and brain volumetric technologies in highly regulated healthcare environments.
“Steve’s deep experience in building scalable commercial organizations and his understanding of complex healthcare markets make him an ideal leader for Brainreader’s next phase of growth,” said Mads Fiig, Chief Executive Officer of Brainreader. “As demand for AI-driven neuroimaging and brain volumetrics continues to accelerate, Steve will play a critical role in expanding our U.S. footprint and strengthening partnerships with health systems nationwide.”
“Lasting impact in healthcare comes from turning clinical innovation into solutions that scale, integrate, and truly change patient care,” said Green. “I’m excited to join Brainreader at a pivotal time and help accelerate adoption of AI-driven brain volumetric solutions that deliver meaningful clinical and operational value.”
As Head of U.S. Sales, Mr. Green will focus on strengthening Brainreader’s commercial infrastructure, expanding strategic partnerships, and supporting continued growth as demand for AI-enabled neuroimaging and brain volumetrics continues to increase across the U.S. healthcare market.